ARS Pharmaceuticals has pleased its acquirer with the news that the US regulator will review its lead drug candidate.
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Neffy (epinephrine nasal spray), an emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs), filed by ARS Pharma, which Silverback Therapeutics (Nasdaq: SBTX) is in the process of acquiring
In July this year, Silverback and privately-held ARS Pharma announced they had entered into a definitive agreement under which the companies are merging in an all-stock transaction, which has not yet completed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze